OrganiGram Holdings Inc (TSX:OGI) (OTCQX:OGRMF) – Company Profile
Quote Close Prices Trades Chart News Company Analyst Corp. Events Share Info Key Ratios Filings Earnings

OrganiGram Holdings Inc Company Profile

Based in Moncton, New Brunswick, OrganiGram Holdings Inc (TSXV:OGI) (OTCQX:OGRMF) is a leading licensed producer of premium quality dried cannabis and cannabis oil for the medical and adult recreational markets. OrganiGram is one of three cannabis companies present in all 10 provinces in Canada and is expanding its footprint beyond the country with international partnerships. The company has a market cap of $1.4 billion as well as the lowest cost of cultivation of Canadian cannabis producers, driving industry-leading adjusted gross margin. 

OrganiGram has created a portfolio of legal adult-use recreational cannabis brands that include Edison Cannabis CompanyAnkr Organics, Trailer Park Buds, and Trailblazer

Being located in New Brunswick offers the company a number of benefits. Not only does New Brunswick have the lowest general corporate income tax in Atlantic Canada, but it is also one of the lowest cost locations in Canada regarding operating cost, wages, utilities, and real estate. Thanks to this, OrganiGram Holdings Inc is well positioned to become a leading producer in the medical cannabis market and adult recreational market.

In addition to its location and testing of products with third-party lab testing, OrganiGram has enough credibility to establish a significant customer base in the adult recreational market, as well as to create and develop differentiated and branded products. It also has access to the Canopy Growth customer base, having signed a two-year supply deal with one of the biggest players in the Canadian cannabis industry.

OrganiGram has been focused on expanding the production capacity at its primary facility in Moncton, New Brunswick. Construction at the unique three-level production facility is currently in Phase 4, which will more than triple its capacity to 113,000 kilograms per year and make it the seventh-largest Canadian cannabis producer in regards to capacity. The expansion includes a state-of-the-art mechanical system and an improved irrigation system that is expected to be one of the most sophisticated in North America.

Outside of Canada, OrganiGram Holdings is well-positioned in international medical cannabis markets, which can be credited to several of its strategic investment. In Germany, the company has partnered with Alpha-Cannabis, which gives OrganiGram an immediate vehicle for larger scale export into the European market, while in Australia, OrganiGram can commence international export to its partner Cannatrek Medical.


Well-Positioned for the Edibles, Derivatives and CBD Markets

OrganiGram is well-positioned for the cannabis edibles market, which is expected to grow significantly once legalized in Canada this coming fall. In fact, experts are predicting the legal cannabis edibles market in Canada and the US will reach $4.1 billion by 2022. The company signed an exclusive consulting agreement with The Green Solution (TGS), a proven US market leader for commercial-scale extraction, product processing, and derivative product development. 

In January 2019, OrganiGram partnered with Canada's Smartest Kitchen to expand its edible research and development and develop premium chocolate cannabis products. The partnership will see Canada's Smartest Kitchen, a leader in food product development, take a detailed look at current Canadian food flavor, color and texture trends, and conduct research to explore the different expectations and needs of medical and recreational cannabis consumers. This includes an in-depth investigation of consumers' preferred product formats,  functions, applications, and product profiles that will add to the OrganiGram's existing and growing expertise.

OrganiGram has invested in disruptive technology through its strategic partnership with Hyasynth, a biotech company that has developed a proprietary technology to naturally produce CBD through engineered yeast strains. Access to this technology will help OrganiGram produce pure CBD at half the cost of extracting from plants.

OrganiGram is also creating strategic relationships within the global CBD market, which is estimated to reach $22 billion USD by 2022. In October, the company partnered with Eviana to purchase up to 25% of its raw CBD oil at a discount. Then, in January 2019, OrganiGram signed an agreement with 1812 Hemp to secure supply and support R&D on the genetic improvement of hemp in order to maximize yields and reduce costs. 

OrganiGram wants to move into the cannabis beverage space as well and is seeking a strategic partner with proven experience in the beverage product development space.


Improving Compassionate Care Access for Patients

OrganiGram is committed to providing medical cannabis patients with access to high-quality products to help with their needs, even if they cannot afford it. This is why the company made changes to its compassionate care model in January by developing OrganiCare, a program designed to improve access to medical cannabis for patients with low income.

OrganiCare is available to patients who earn an annual income that is less than $35,000 per year and will give them a 30% price reduction on all prescribed dried cannabis and oils from OrganiGram. The company's previous compassionate care program was voted best in Canada at the Canadian Cannabis Awards in 2017.

"We understand cost can be a barrier to medication for patients," says Greg Engel, CEO, Organigram. "It is important to us to do what we can to improve access for patients who need it the most. It's our hope that OrganiCare will allow a greater number of patients to access their medicine."

The enhanced program will be available to new and existing patients. To apply, clients can simply fill out a form and attach the necessary documents.



Quality. Confidence. Trust.

At OrganiGram, client safety and product quality are a top priority, which is why the company has established its Seven Steps of Quality Commitment

OrganigGram’s Seven Steps of Quality Commitment include:

1. Testing every product lot for pesticides far beyond regulatory requirements

2. Regular testing of inputs like seeds, growing medium, fertilizers, and water from outside suppliers before they are used

3. Extending its Integrated Pest Management (IPM) operating procedures to include periodic live plant sampling for pesticide screening

4. Following formal program for receiving, securing and testing critical inputs on a routine basis

5. Pre-qualifying suppliers using a comprehensive screening process before they are approved to do business with Organigram

6. Using industry-leading closed-circuit camera coverage throughout our facility

7. Formally educating and training regime all of its employees, with a focus on product quality, safety, and consistency

OrganiGram also offers its medical cannabis patients a Certificate of Analysis for available strains to provide full transparency and unparalleled client comfort and confidence. 

By providing a multi-disciplinary approach to post-traumatic stress disorder treatment, trauma therapy, and chronic pain, and medical cannabis as alternative medicine, the New Brunswick-based company will retain its consumer base for years to come.


OrganiGram Holdings Products

With its belief that medical cannabis should be accessible to everyone, OrganiGram offers an array of cannabis products, including dry bud, oils, and vaporizers that can be purchased online or through its cross-platform patient-focused mobile app.

OrganiGram's products are made up of indica, sativa, and CBD strains. Products work differently for everyone, so OrganiGram is here to help patients discover what strains and methods work best for them. One of the ways OrganiGram does this is through its Strain Discovery Kit.

OrganiGram Holdings Inc

The Strain Discovery Kit contains three five-gram bottles—one with an indica strain, one with a sativa strain, and one with a CBD strain. With this kit, patients can figure out which strain works best for them. Once the appropriate strain has been determined, patients can choose from OrganiGram's list of products using their ideal strain.

OrganiGram's products include cannabis buds, cannabis oils, and vaporizers.

The cannabis oils are organically grown and include Utopia (CBD), Shubie (CBD), Banook (indica), and Rossignol (sativa). Buds include Lighthouse, Torbay, Hunter's Corner, and Low Tide for indica, and Wabanaki and High Tide for sativa. Low Tide and High Tide are pre-milled premium blends, while Hunter's Corner is a hash plant.

OrganiGram also has several vaporizers, including The Volcano, Mighty, Crafty, Pax 2, Pax 3, Davinci IQ, Arizer Extreme Q, and Zeus Smite.


Signing Up with OrganiGram Holdings Inc

OrganiGram makes it easy to sign up. You can do so online or you can mail in the necessary documents. Either way, it just takes three steps.

OrganiGram Holdings Inc

The first step is to register. The OrganiGram registration form walks you through step-by-step on all the necessary information—basic contact information, caregiver options, Prescription Reminder Program opt-in, the likes.

You can register online or print out the form and send it in.

OrganiGram Holdings Inc

The next step is to get your doctor to fill out OrganiGram's medical form. This is required to be eligible for the program and needs to be received by the company before you can finish registering.

The medical form will need to be printed out and given to your doctor.

OrganiGram Holdings Inc

Once you have filled out your registration form and gotten your doctor to fill out and sign the medical form, you're all set to go! Time to order some products!

One of the benefits of registering with OrganiGram is its introductory offers, veteran support, OrganiCare, Renewal Reminder Program, support programs, competitive vaporizer pricing, and the Strain Discovery Program.

New registrants will also receive a Welcome Kit to help you get the best out of your OrganiGram products. This kit includes a client card, a Medtainer, and Aunt Sandy's Medical Marijuana Cookbook.


Meet the Organigram Team

Gregory Engel - Chief Executive Officer 

Gregory Engel brings over 30 years of experience in the pharmaceutical industry to his role as the Chief Executive Officer at OrganiGram. He also has more than three years of experience as a CEO of a cannabis company.

Paolo DeLuca - Chief Financial Officer

Paolo DeLuca is the Chief Financial Officer at OrganiGram. Paolo has 20 years of diversified financial business experience that includes working for companies like TD Securities and West Face Capital.

Tim Emberg - Sr. VP of Sales and Commercial Operations

Tim Emberg is the Senior Vice President of Sales and Commercial Operations at OrganiGram. He has 20 years of experience in pharmaceutical sales and marketing in the OTC and consumer packaged goods industry. Prior to joining OrganiGram, Tim worked for Roche Diabetes Care Canada, Frito-Lay Canada, and Jamieson Laboratories.

Ray Gracewood - Sr. VP of Marketing and Communications

Ray Gracewood brings 15 years of experience to his role as Senior Vice President of Marketing and Communications at OrganiGram. Prior to OrganiGram, Ray served as the senior director of sales and marketing at Moosehead Breweries Ltd.

Jeff Purcell - Sr. VP of Operations 

Jeff Purcell is the Senior Vice President of Operations at OrganiGram. Jeff brings with him 25 years of experience in operations for companies like McCain Foods and Ganong Chocolates.

Larry Rogers - VP of International Sales

Larry Rogers is the Vice President of International Operations at OrganiGram. Prior to this role, he served as a member of the Board of Directors, Chief Operations Officer and VP of Business Development at the company. Larry also spent time working for a Swiss private equity firm with offices in Western Europe, North America, and Asia.


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Organigram Holdings Inc. Market Jar Media Inc. has or expects to receive one hundred and forty-five thousand five hundred Canadian dollars from Organigram Holdings Inc.’s agency of record Native Ads Inc. for 14 campaign days (10 business days).

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on Potstocknews.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Potstocknews.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.